Smruthi Vijayaraghavan

1.4k total citations
15 papers, 914 citations indexed

About

Smruthi Vijayaraghavan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Smruthi Vijayaraghavan has authored 15 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Smruthi Vijayaraghavan's work include Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (7 papers) and Lung Cancer Treatments and Mutations (4 papers). Smruthi Vijayaraghavan is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer-related Molecular Pathways (7 papers) and Lung Cancer Treatments and Mutations (4 papers). Smruthi Vijayaraghavan collaborates with scholars based in United States, South Korea and United Kingdom. Smruthi Vijayaraghavan's co-authors include Khandan Keyomarsi, Kelly K. Hunt, Tuyen Bui, Cansu Karakaş, Sheri L. Moores, Xian Chen, Yang Zhao, Jason P.W. Carey, Kavitha Balaji and Jing Wang and has published in prestigious journals such as Nature Communications, Cancer Research and Oncogene.

In The Last Decade

Smruthi Vijayaraghavan

14 papers receiving 908 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Smruthi Vijayaraghavan United States 10 571 412 352 126 110 15 914
Cansu Karakaş United States 18 608 1.1× 433 1.1× 374 1.1× 213 1.7× 49 0.4× 36 1.0k
François Ringeisen France 14 373 0.7× 517 1.3× 305 0.9× 175 1.4× 72 0.7× 33 899
Ahrum Min South Korea 16 635 1.1× 634 1.5× 181 0.5× 123 1.0× 72 0.7× 36 957
Alberto Servetto Italy 16 394 0.7× 512 1.2× 271 0.8× 208 1.7× 59 0.5× 56 897
Graziana Digiacomo Italy 18 459 0.8× 337 0.8× 424 1.2× 152 1.2× 108 1.0× 25 821
Raul Ayala United States 9 356 0.6× 483 1.2× 253 0.7× 124 1.0× 55 0.5× 18 830
Cuiju Tang China 14 340 0.6× 382 0.9× 240 0.7× 178 1.4× 96 0.9× 47 853
Andrea Gombos Belgium 15 529 0.9× 303 0.7× 239 0.7× 210 1.7× 112 1.0× 40 805
Yun Oh United States 18 373 0.7× 561 1.4× 310 0.9× 137 1.1× 115 1.0× 28 1.0k
Samuel W. Brady United States 14 588 1.0× 608 1.5× 188 0.5× 187 1.5× 93 0.8× 25 1.1k

Countries citing papers authored by Smruthi Vijayaraghavan

Since Specialization
Citations

This map shows the geographic impact of Smruthi Vijayaraghavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Smruthi Vijayaraghavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Smruthi Vijayaraghavan more than expected).

Fields of papers citing papers by Smruthi Vijayaraghavan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Smruthi Vijayaraghavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Smruthi Vijayaraghavan. The network helps show where Smruthi Vijayaraghavan may publish in the future.

Co-authorship network of co-authors of Smruthi Vijayaraghavan

This figure shows the co-authorship network connecting the top 25 collaborators of Smruthi Vijayaraghavan. A scholar is included among the top collaborators of Smruthi Vijayaraghavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Smruthi Vijayaraghavan. Smruthi Vijayaraghavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Henley, Benjamin J., Stacey L. Lehman, Himanshu Gupta, et al.. (2024). Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression. npj Precision Oncology. 8(1). 192–192. 6 indexed citations
2.
Henley, Benjamin J., Himanshu Gupta, Smruthi Vijayaraghavan, et al.. (2024). Abstract 1914: Amivantamab efficacy in wildtype EGFR NSCLC tumors correlates with levels of ligand expression. Cancer Research. 84(6_Supplement). 1914–1914.
3.
4.
Vijayaraghavan, Smruthi, Lorraine Lipfert, Kristen Chevalier, et al.. (2020). Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Molecular Cancer Therapeutics. 19(10). 2044–2056. 138 indexed citations
5.
Chen, Xian, Angela Alexander, Yufeng Jiang, et al.. (2018). Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research. 24(24). 6594–6610. 78 indexed citations
6.
Carey, Jason P.W., Cansu Karakaş, Tuyen Bui, et al.. (2017). Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research. 78(3). 742–757. 103 indexed citations
7.
Francis, Ashleigh M., Angela Alexander, Yanna Liu, et al.. (2017). CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics. 16(9). 1751–1764. 41 indexed citations
8.
Vijayaraghavan, Smruthi, Cansu Karakaş, Iman Doostan, et al.. (2017). CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications. 8(1). 15916–15916. 213 indexed citations
9.
Vijayaraghavan, Smruthi, Iman Doostan, Jason P.W. Carey, & Khandan Keyomarsi. (2017). Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer. Cancer Research. 77(13_Supplement). 2060–2060. 6 indexed citations
10.
Vijayaraghavan, Smruthi, Stacy Moulder, Khandan Keyomarsi, & Rachel M. Layman. (2017). Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Targeted Oncology. 13(1). 21–38. 67 indexed citations
11.
Jinesh, Goodwin G., Vaishnavi Sambandam, Smruthi Vijayaraghavan, Kavitha Balaji, & Subhajit Mukherjee. (2017). Molecular genetics and cellular events of K-Ras-driven tumorigenesis. Oncogene. 37(7). 839–846. 70 indexed citations
12.
Chen, Xian, Tuyen Bui, Yufeng Jiang, et al.. (2016). Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 15(4). 593–607. 51 indexed citations
13.
Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58. 70 indexed citations
14.
Vijayaraghavan, Smruthi & Khandan Keyomarsi. (2015). Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers. Cancer Research. 75(9_Supplement). P5–8. 1 indexed citations
15.
Vijayaraghavan, Smruthi & Khandan Keyomarsi. (2015). Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer. Cancer Research. 75(15_Supplement). 1783–1783. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cansu Karakaş Breakdown of academic impact, for papers by François Ringeisen Breakdown of academic impact, for papers by Ahrum Min Breakdown of academic impact, for papers by Alberto Servetto Breakdown of academic impact, for papers by Graziana Digiacomo Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Cuiju Tang Breakdown of academic impact, for papers by Andrea Gombos Breakdown of academic impact, for papers by Yun Oh Breakdown of academic impact, for papers by Samuel W. Brady
Rankless by CCL
2026